Recursion Pharmaceuticals, Inc.
General ticker "RXRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.2B (TTM average)
Recursion Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -5.9%.
Estimated limits based on current volatility of 2.4%: low 2.99$, high 3.13$
Factors to consider:
- Earnings expected soon, date: 2026-08-04 bmo
- Total employees count: 800 (+60.0%) as of 2024
- Top business risk factors: Limited operating history, No approved products, Regulatory and compliance, Product development failure, Capital raising
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.77$, 6.83$]
- 2026-12-31 to 2027-12-31 estimated range: [2.83$, 6.90$]
Financial Metrics affecting the RXRX estimates:
- Positive: with PPE of -2.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -19.56 <= 0.30
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 76.71 > 63.79
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: -4.44 < Investing cash flow per share per price, % of -0.89
Short-term RXRX quotes
Long-term RXRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $44.58MM | $58.84MM | $74.68MM |
| Operating Expenses | $394.63MM | $537.84MM | $722.81MM |
| Operating Income | $-350.06MM | $-479.00MM | $-648.13MM |
| Non-Operating Income | $17.93MM | $14.22MM | $3.24MM |
| R&D Expense | $241.23MM | $314.42MM | $475.27MM |
| Income(Loss) | $-332.13MM | $-464.79MM | $-644.89MM |
| Taxes | $-4.06MM | $-1.13MM | $-0.14MM |
| Net Income(Loss)* | $-328.07MM | $-463.66MM | $-644.76MM |
| Stockholders Equity | $463.44MM | $1,034.78MM | $1,130.87MM |
| Assets | $653.70MM | $1,448.60MM | $1,474.13MM |
| Operating Cash Flow | $-287.78MM | $-359.17MM | $-371.81MM |
| Capital expenditure | $11.96MM | $13.70MM | $6.47MM |
| Investing Cash Flow | $-10.23MM | $260.06MM | $-16.87MM |
| Financing Cash Flow | $140.13MM | $304.12MM | $521.53MM |
| Earnings Per Share** | $-1.58 | $-1.69 | $-1.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.